February 6, 2023
DRDO invites EoI to transfer technology of 2-DG drug for bulk production | India News - Times of India


HYDERABAD: The Defence Research and Development Organisation (DRDO), which developed 2-Deoxy-D- Glucose (2-DG), a drug used for therapy of Covid-19 sufferers, has referred to as for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production.
2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’s Laboratories.
Clinical trial outcomes have proven that this molecule helps in sooner restoration of hospitalised sufferers and reduces supplemental oxygen dependence.
Higher proportion of sufferers handled with 2-DG confirmed RT-PCR destructive conversion in Covid sufferers. According to the EoI doc, functions ought to be submitted earlier than June 17 by way of e mail.
“The EoI submitted by industries will be scrutinised by a Technical Assessment Committee (TAC). Only up to 15 industries will be given ToT on their capabilities, technical hand holding capability of DRDO and on First Come First Served Basis,” it stated.
The bidders ought to have a Drug license to manufacture Active Pharmaceutical Ingredient (API) from Drug Licensing Authorities and WHO GMP (Good manufacturing Practices) certification amongst others.
Laboratory synthesis course of for 2-DG has been developed utilizing D-Glucose as beginning materials. The synthesis course of consists of conversion of D-Glucose to 2-DG by way of 5 chemical response steps adopted by purification.
The course of has been established at batch scale (100g) and pilot plant scale (500g) and vital patents have been filed by DRDO on this regard, the Defence physique stated.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *